Biblio Discovery — Demo Discovery Service

4 hasil untuk "Siegbert Rossol"

Menampilkan 1–4 · 0,21 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany

    Jona T. Stahmeyer; Siegbert Rossol; Sebastian Liersch dkk.

    PLOS ONE, Vol. 12 No. 1 · 2017 · Inggris · PLOS Scopus

    Background: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained…

  2. Artikel Jurnal Teks lengkap

    Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models

    Leonie Diedrich; Melanie Brinkmann; Maren Dreier dkk.

    PLOS ONE, Vol. 18 No. 8 · 2023 · Inggris · PLOS Scopus

    Introduction: Screening for colorectal cancer (CRC) is effective in reducing both incidence and mortality. Colonoscopy and stool tests are most frequently used for this purpose. Sigmoidoscopy is an alternative screening measure with a strong evidence base. Due to its distinct characteristics, it…

  3. Artikel Jurnal Teks lengkap

    Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)”

    Kathrin Krüger; Carina Oedingen; Achim Kautz dkk.

    PLOS ONE, Vol. 18 No. 7 · 2023 · Inggris · PLOS Scopus

    Background: Non-alcoholic steato-hepatitis (NASH) is the inflammatory, progressive form of non-alcoholic fatty liver disease (NAFLD). A delayed diagnose interval is typical for the majority of the patients because of the asymptomatic natural course. However, serious sequelae may develop such as…

  4. Artikel Jurnal Teks lengkap

    Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study

    Jona T. Stahmeyer; Siegbert Rossol; Florian Bert dkk.

    PLOS ONE, Vol. 11 No. 7 · 2016 · Inggris · PLOS Scopus

    1. Objective: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side…